Manuel A. Montoya-Hernandez

Manuel A. Montoya-Hernandez

Auto-generated profile, based on publicly available information

Manuel A. Montoya-Hernandez

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2025 in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
Verified
Journal Article
Open access
PDF file
ARArturo M. Ruiz-Beltrán
Arturo M. Ruiz-Beltrán
GCGerardo Chacón-Loyola
Gerardo Chacón-Loyola
RBRicardo L. Barajas-Campos
Ricardo L. Barajas-Campos
AAAlejandro Alcaraz-Guzmán
Alejandro Alcaraz-Guzmán
MMManuel A. Montoya-Hernández
Manuel A. Montoya-Hernández
LRLaura L. Rodríguez-Chávez
Laura L. Rodríguez-Chávez
Objective. To evaluate the predictive ability of traditional risk scores and frailty assessment for 30-day mortality in elderly patients undergoing cardiac surgery. Materials and Methods. A single-center retrospective cohort study was conducted, including elderly patients (≥75 years old) who underwent cardiac surgery between January 2005 and December 2015. EuroSCORE II, STS (Society of Thoracic Surgeons) score, Charlson Comorbidity Index, and Electronic Frailty Index scores were calculated to assess their predictive ability for 30-day mortality using receiver operating characteristic (ROC) curves and corresponding areas under the curve (AUC). Results. A total of 203 patients were included during the study period, of whom 33% underwent isolated coronary bypass surgery. The overall 30- day mortality rate was 17.6%. Patients who died within the first 30 days exhibited higher scores on EuroSCORE II, STS, and the Electronic Frailty Index. The areas under the ROC curves were: EuroSCORE II, 0.74 (95% CI: 0.66-0.81); STS, 0.66 (95% CI: 0.57-0.77); Charlson Comorbidity Index, 0.60 (95% CI: 0.49-0.70); and Electronic Frailty Index, 0.63 (95% CI: 0.52-0.73). Conclusions. In this cohort of elderly patients undergoing cardiac surgery, EuroSCORE II demonstrated the best performance in predicting 30-day mortality.

17 September 2026 in Journal of the Heart Valve Society
Verified
Journal Article
Open access
MMManuel A. Montoya-Hernandez
Manuel A. Montoya-Hernandez
FLFrancisco Lope-Jimenez
Francisco Lope-Jimenez
TPTimothy J. Poterucha
Timothy J. Poterucha
KLKan Liu
Kan Liu
JMJose R. Medina-Inojosa
Jose R. Medina-Inojosa
HMHector I. Michelena
Hector I. Michelena
Background: Bicuspid aortic valve (BAV) is the most common congenital heart defect, associated with a lifetime morbidity burden exceeding 80% and an estimated 7% probability of transmission to first-degree relatives. Hence, echocardiographic screening of relatives is recommended. The aim of our study is to develop an artificial intelligence-enabled electrocardiogram (AI-ECG) model for the detection of BAV. Methods: Between January 1, 1990, and June 30, 2023, the Mayo Clinic healthcare system database was searched for patients aged ≥18 years with echocardiograms performed for family history of BAV, abnormal auscultation, a BAV-related diagnosis, or to rule out the condition, and with an electrocardiogram (ECG) obtained within 6 months. Cases were patients with a confirmed BAV diagnosis, and controls were those with normal aortic valves. ECGs were randomly assigned into training (80%), internal validation (10%), and test (10%) groups. The AI-ECG model was built using Keras under TensorFlow. Results: A total of 13,065 valid ECG–echocardiogram pairs were included (mean [SD] age, 58 [17] years; 44% women), with a median time of 1 day (interquartile range, 0–3 days) between studies. With a 45% BAV prevalence in the test group ( n = 1301), the area under the curve was 0.704, positive predictive value (PPV) 60.1%, and negative predictive value (NPV) 69.4%. At a prevalence of 7%, the NPV increased to 96.1%, but the PPV decreased to 12.2%. Conclusions: In this retrospective cohort and using the current AI-ECG model, BAV detection showed modest diagnostic performance and limited standalone clinical utility, suggesting that ECG-only screening for BAV may require additional modalities or more refined phenotyping.